<DOC>
	<DOCNO>NCT00966563</DOCNO>
	<brief_summary>The present feasibility study design find whether pre-treatment compound mangafodipir ( PP-099 ) provide additional reduction myocardial infarct size patient treat primary percutaneous coronary intervention ( PCI ) acute myocardial infarction ( AMI ) .</brief_summary>
	<brief_title>Mangafodipir Adjunct Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Mangafodipir , manganese ( Mn ) dipyridoxyl diphosphate ( MnDPDP ) lipophile metabolite Mn dipyridoxyl diethylene diamide ( MnPLED ) , catalytic antioxidant iron chelators . In preclinical study agent reduce oxidative stress induce injury relate chemotherapy cancer reperfusion/reoxygenation ischemic/hypoxic myocardium . Accordingly , vivo pig model AMI metabolite MnPLED apply end ischemia reperfusion reduce myocardial infarct size 55 % . Mangafodipir likely activate salvage pathway prevents lethal reperfusion injury . Other advantage mangafodipir already approve contrast agent MRI liver , experience decade reveals high safety minor tolerable side-effects . The present study include 20 patient treat first document AMI . They admission hospital undergo primary PCI . Reopening occlude coronary artery precede iv . infusion mangafodipir placebo two group , consist 10 patient . The primary endpoint release plasma commonly accept biomarkers myocardial injury ( Troponin T CK-MB ) measure admission 6 hour PCI . The secondary endpoint include accumulated release plasma biomarkers 48 hour direct measurement final myocardial infarct size 6-10 week PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<criteria>1 . Males 4080 female 5080 year first severe coronary attack 2 . Chest pain 6 hour . 3 . T segment elevation ( ≥ 0.2 mV two neighbour anterior inferior wall lead . 4 . Decided treatment primary PCI . 5 . TIMI grade 0 flow occlude LAD RCA artery 6 . Written informed consent . 1 . Previous coronary artery bypass operation . 2 . Previous AMI . 3 . Chest pain 6 hour . 4 . Angina within 48 hour admission . 5 . Cardiac arrest cardiogenic shock . 6 . Occlusion leave main stem , circumflex right coronary artery angiography . 7 . Known hypersensitivity mangafodipir ( contrast agent MRI ) . 8 . Received mangafodipir ≤ 5 week admission 9 . History prior serious allergic pseudoallergic reaction 10 . Severely reduced liver renal function 11 . Any serious illness medical condition 12 . Fertile females 13 . Phaeochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Mangafodipir</keyword>
	<keyword>Primary Percutaneous Coronary Intervention</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Troponin</keyword>
	<keyword>CK-MB</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>